HealthInvest Partners AB Has $1.37 Million Position in Mereo BioPharma Group plc (NASDAQ:MREO)

HealthInvest Partners AB raised its stake in shares of Mereo BioPharma Group plc (NASDAQ:MREO) by 95.0% during the 4th quarter, HoldingsChannel reports. The firm owned 390,000 shares of the company’s stock after purchasing an additional 190,000 shares during the quarter. HealthInvest Partners AB’s holdings in Mereo BioPharma Group were worth $1,373,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of MREO. Newbridge Financial Services Group Inc. acquired a new position in Mereo BioPharma Group in the 4th quarter valued at $37,000. Golden State Equity Partners boosted its holdings in Mereo BioPharma Group by 247.7% during the fourth quarter. Golden State Equity Partners now owns 22,600 shares of the company’s stock valued at $79,000 after acquiring an additional 16,100 shares during the period. PFG Investments LLC grew its position in shares of Mereo BioPharma Group by 132.0% in the fourth quarter. PFG Investments LLC now owns 39,433 shares of the company’s stock valued at $138,000 after purchasing an additional 22,433 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Mereo BioPharma Group in the fourth quarter worth about $69,000. Finally, Frazier Life Sciences Management L.P. lifted its position in shares of Mereo BioPharma Group by 15.8% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 5,097,779 shares of the company’s stock worth $20,952,000 after purchasing an additional 696,408 shares during the last quarter. Institutional investors own 62.83% of the company’s stock.

Analyst Ratings Changes

MREO has been the topic of a number of research analyst reports. Lifesci Capital began coverage on Mereo BioPharma Group in a report on Tuesday, December 24th. They issued an “outperform” rating and a $10.00 target price on the stock. Cantor Fitzgerald raised shares of Mereo BioPharma Group to a “strong-buy” rating in a research report on Sunday, December 8th. Jefferies Financial Group started coverage on shares of Mereo BioPharma Group in a research note on Friday, December 6th. They set a “buy” rating and a $7.00 target price for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $7.00 price target on shares of Mereo BioPharma Group in a research report on Monday, January 13th. Four investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Mereo BioPharma Group presently has a consensus rating of “Buy” and a consensus price target of $7.83.

Mereo BioPharma Group Stock Performance

Shares of NASDAQ MREO opened at $2.86 on Monday. Mereo BioPharma Group plc has a one year low of $2.78 and a one year high of $5.02. The business has a fifty day simple moving average of $3.21 and a 200 day simple moving average of $3.81.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.